Table of Contents
ISRN Gastroenterology
Volume 2011, Article ID 645641, 8 pages
http://dx.doi.org/10.5402/2011/645641
Research Article

Immunoreactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Epithelial Malignant Tumors from Digestive System

1Department of Quality Control, Center of Molecular Immunology, Havana 11600, Cuba
2Department of Pathology, Manuel Fajardo General Hospital, Havana 10400, Cuba
3Laboratory of Molecular Oncology, Department of Science and Technology, Quilmes National University, Buenos Aires, Bernal B1876BXD, Argentina
4Research and Development Direction, Center of Molecular Immunology, 216 Street and 15 Avenue Atabey, Playa. P.O. Box 16040, Havana 11600, Cuba

Received 21 September 2010; Accepted 3 November 2010

Academic Editors: D. Coppola and M. de Bernard

Copyright © 2011 Rancés Blanco et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The limited expression of N-Glycolyl GM3 (NeuGcGM3) ganglioside in human normal tissues, as well as its presence in melanoma and breast carcinoma using 14F7 Mab (anti-NeuGcGM3), has been previously reported. In this work we evaluated for the first time the 14F7 Mab immunorecognition in some digestive system tumors. Immunohistochemical assays were made with 14F7, followed by anti-mouse biotinylated antibody and ABC/HRP system in normal and pathological human tissues were made. No immunoreaction was evidenced in normal tissues. The reactivity of 14F7 was detected in all adenocarcinomas of the stomach (12/12), colon (12/12), and pancreas (11/11). A finely granular immunorecognition in esophageal tumors (5/15), epidermoid carcinoma of the rectum (5/7), and basaloid carcinoma (4/5) of the latter as well as in hepatocellular carcinoma (13/14) was also observed. Our results are in agreement with the assumption that NeuGcGM3 ganglioside may be considered as target for passive and active immunotherapy in digestive system malignancies expressing this molecule.